Evidence map›Paper›PMID 40830572›Full record

ArticleCommunications biology2025

HybriSeq: probe-based device-free single-cell RNA profiling.

Daniel Foyt, David Brown, Shuqin Zhou, Brittany Moser, Qin Zhu, Zev J Gartner, Bo Huang

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Daniel FoytUCSF-UC Berkeley Joint Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA.
David BrownDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7531-8230
Shuqin ZhouDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Brittany MoserDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Qin ZhuDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Zev J GartnerDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7803-1219
Bo HuangDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA. bo.huang@ucsf.edu.ORCID http://orcid.org/0000-0003-1704-4141

Funding

Modulation and functional characterization of protein condensation in chromatin organizationU01DK127421 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, BO, NARLIKAR, GEETA J · 2020 to 2024
$5.4M
Cancer Research Institute (CRI) CRI5054NIDDK NIH HHS U01 DK127421U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01DK127421
6 · The paper itself

Abstract

We have developed the HybriSeq method for single-cell RNA profiling, which utilizes in situ hybridization of multiple probes for targeted transcripts, followed by split-pool barcoding and sequencing analysis of the probes. We have shown that HybriSeq can achieve high sensitivity for RNA detection with multiple probes and profile entire transcripts without an end bias. The utility of HybriSeq is demonstrated in characterizing cell-to-cell heterogeneities of a panel of 196 genes in peripheral blood mononuclear cells and the detection of missed annotations of transcripts.

Indexed as

Gene Expression ProfilingHigh-Throughput Nucleotide SequencingRNASequence Analysis, RNASingle-Cell AnalysisHumansIn Situ HybridizationLeukocytes, MononuclearRNA

Identifiers

PMID40830572
PMCPMC12365068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.